Profile data is unavailable for this security.
About the company
Jiangsu Kanion Pharmaceutical Co Ltd is a China-based company principally engaged in the research and development, production, and sales of drugs. The Company's respiratory and infectious disease product line includes Jin Zhen oral liquid, Re Du Ning injection and others. The Company's cardiovascular and cerebrovascular product line includes Ginkgo biloba diterpenoid lactone glucosamine injection, Tianshu capsules and others. The Company's gynecological product line includes Guizhi Fuling Capsules, Sanjie Analgesic Capsules and others. The Company's orthopedics and traumatology product line includes compound Nanxing pain relieving cream, Yaobitong capsule, Jingu pain relieving gel and others. The Company is also engaged in the research and development of chemical drugs and biological drugs. The Company mainly conducts its business in the domestic market.
- Revenue in CNY (TTM)3.13bn
- Net income in CNY234.36m
- Incorporated1996
- Employees6.13k
- LocationJiangsu Kanion Pharmaceutical Co LtdJiangning Industrial ParkEconomic & Technological Development ZneLIANYUNGANG 222047ChinaCHN
- Phone+86 51 885521990
- Fax+86 51 885521990
- Websitehttps://www.kanion.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| China Animal Husbandry Industry Co., Ltd | 6.28bn | 214.44m | 7.98bn | 4.30k | 37.19 | 1.39 | -- | 1.27 | 0.21 | 0.21 | 6.15 | 5.60 | 0.6863 | 5.30 | 4.19 | 1,461,064.00 | 2.32 | 5.25 | 3.37 | 7.48 | 15.59 | 22.15 | 3.38 | 7.31 | 1.62 | -- | 0.1625 | 31.16 | 11.30 | 7.79 | -82.41 | -22.24 | -0.0699 | -21.83 |
| Zhejiang Ausun Pharmaceutical Co Ltd | 751.12m | 184.84m | 8.20bn | 1.22k | 44.04 | 3.49 | -- | 10.91 | 0.2241 | 0.2241 | 0.8963 | 2.83 | 0.2472 | 0.9248 | 3.00 | 616,180.10 | 6.08 | 8.91 | 7.77 | 12.10 | 51.51 | 53.44 | 24.61 | 27.68 | 2.17 | -- | 0.1383 | 27.35 | -2.63 | 20.90 | -18.55 | 29.68 | 17.53 | 43.79 |
| Guangxi Wuzhou Zhongheng Group Co Ltd | 2.29bn | -363.56m | 8.22bn | 2.97k | -- | 1.42 | -- | 3.58 | -0.1112 | -0.1112 | 0.7189 | 1.82 | 0.204 | 2.09 | 3.30 | 771,487.60 | -4.90 | -0.1745 | -7.79 | -0.2739 | 34.13 | 64.36 | -24.05 | -0.6631 | 2.01 | -5.26 | 0.2563 | 69.54 | -26.67 | -9.85 | -547.14 | -- | 4.41 | -- |
| Changchun BCHT Biotechnology Co | 677.51m | -170.53m | 8.31bn | 1.27k | -- | 2.10 | -- | 12.27 | -0.4124 | -0.4124 | 1.64 | 9.57 | 0.1288 | 0.7183 | 0.4756 | 531,801.10 | -3.24 | 8.14 | -4.12 | 10.19 | 77.22 | 85.58 | -25.17 | 23.29 | 1.20 | -8.89 | 0.0696 | 14.91 | -32.64 | 4.73 | -53.67 | 0.9824 | 33.40 | -- |
| Sichuan Huiyu Pharmaceutical Co Ltd | 984.29m | 47.23m | 8.31bn | 1.38k | 175.96 | 2.23 | -- | 8.44 | 0.1115 | 0.1115 | 2.32 | 8.81 | 0.1983 | 0.9536 | 14.36 | 712,220.30 | 0.8073 | 8.62 | 1.04 | 10.46 | 80.54 | 88.41 | 4.07 | 22.26 | 2.63 | -- | 0.1185 | 24.48 | 18.05 | 9.13 | 132.78 | 12.96 | 3.11 | -- |
| Nanjing Vazyme Biotech Co Ltd | 1.34bn | -29.64m | 8.35bn | 2.87k | -- | 2.17 | -- | 6.21 | -0.0817 | -0.0817 | 3.98 | 9.66 | 0.2715 | 1.10 | 2.75 | 468,919.20 | -0.6649 | 9.69 | -0.8034 | 11.88 | 68.89 | 69.81 | -2.45 | 20.70 | 3.34 | -- | 0.1832 | 35.88 | 7.15 | 38.71 | 74.50 | -- | 30.38 | -- |
| Jiangsu Kanion Pharmaceutical Co., Ltd. | 3.13bn | 234.36m | 8.36bn | 6.13k | 35.71 | 1.77 | -- | 2.67 | 0.4136 | 0.4136 | 5.50 | 8.33 | 0.459 | 2.03 | 5.49 | 510,570.90 | 3.29 | 5.72 | 4.42 | 8.14 | 67.90 | 72.85 | 7.18 | 9.42 | 1.73 | 47.38 | 0.0006 | 18.39 | -19.86 | -3.11 | -15.58 | -5.02 | -0.5518 | -- |
| Holder | Shares | % Held |
|---|---|---|
| China Investment Corp. (Investment Management)as of 31 Mar 2025 | 17.89m | 3.10% |
| Penghua Fund Management Co., Ltd.as of 30 Jun 2025 | 5.33m | 0.92% |
| Da Cheng Fund Management Co., Ltd.as of 31 Mar 2025 | 5.01m | 0.87% |
| Bosera Asset Management Co., Ltd.as of 31 Mar 2025 | 4.80m | 0.83% |
| ICBC UBS Asset Management Co. Ltd.as of 31 Mar 2025 | 4.70m | 0.82% |
| HuaAn Fund Management Co., Ltd.as of 30 Jun 2025 | 3.71m | 0.64% |
| China Southern Asset Management Co., Ltd.as of 30 Jun 2025 | 3.56m | 0.62% |
| China Universal Asset Management Co., Ltd.as of 30 Jun 2025 | 3.19m | 0.55% |
| China Asset Management Co., Ltd.as of 30 Jun 2025 | 2.87m | 0.50% |
| Caitong Fund Management Co., Ltd.as of 30 Jun 2025 | 2.63m | 0.46% |
